Toling Pharmaceuticals Lianhua Qing Plague Capsules was approved by the Mauritian Chinese Medicine Registration.

Lianhua Qing plague products for the company's leading products, the national basic drug catalog and the national health insurance catalog (Class A) varieties, mainly used for cold, influenza-related diseases treatment.
Lianhua Qing plague products have been repeatedly included in the National Health and Health Commission, the State Administration of Traditional Chinese Medicine cold, influenza-related disease diagnosis and treatment program.
2020 Lianhua Qing plague capsules/particles are listed as the National Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "new coronavirus infection of pneumonia diagnosis and treatment program" (trial 4/5/6/7/8 version) recommended medication.
April 12, 2020, the State Drug Administration approved lianhua qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light and common type" on the basis of the original approved adaptation.
2019, the company achieved operating income of 1.703 billion yuan, accounting for 29.24% of the company's total operating income.
first half of 2020, Lianhua Qing plague products achieved operating income of 2,024 million yuan, accounting for 45.11% of the company's total operating income.
So far, Lianhua Qing plague capsules have been registered in Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, Kyrgyzstan, the Philippines and Kuwait as "Traditional Chinese Medicine," "Pharmaceutical," "Plant Medicine," "Natural Health Products," "Food Supplements," "Modern Plant Medicine," "Natural Medicine" and other statuses.
currently accounts for a low proportion of the company's total operating income, which does not have a significant impact on the company's operating performance.
.